FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4225284539> ?p ?o ?g. }

• W4225284539 endingPage "1798" @default.
• W4225284539 startingPage "1785" @default.
• W4225284539 abstract "Pivotal trials of percutaneous left atrial appendage occlusion (LAAO) used specific postprocedure treatment protocols. This study sought to evaluate patterns of postprocedure care after LAAO with the Watchman device in clinical practice and compare the risk of adverse events for different discharge antithrombotic strategies. We evaluated patients in the LAAO Registry of the National Cardiovascular Data Registry who underwent LAAO with the Watchman device between 2016 and 2018. We assessed adherence to the full postprocedure trial protocol including standardized follow-up, imaging, and antithrombotic agents and then evaluated the most commonly used antithrombotic strategies and compared the rates and risk of adverse events at 45 days and 6 months by means of multivariable COX frailty regression. Among 31,994 patients undergoing successful LAAO, only 12.2% received the full postprocedure treatment protocol studied in pivotal trials; the most common protocol deviations were with discharge antithrombotic medications. The most common discharge medication strategies were warfarin and aspirin (36.9%), direct oral anticoagulant (DOAC) and aspirin (20.8%), warfarin only (13.5%), DOAC only (12.3%), and dual antiplatelet therapy (5.0%). In multivariable Cox frailty regression, the adjusted risk of any adverse event through the 45-day follow-up visit were significantly lower for discharge on warfarin alone (HR: 0.692; 95% CI: 0.569-0.841) and DOAC alone (HR: 0.731; 95% CI: 0.574-0.930) compared with warfarin and aspirin. Warfarin alone retained lower risk at the 6-month follow-up. In contemporary U.S. practice, practitioners rarely used the full U.S. Food and Drug Administration–approved postprocedure treatment protocols studied in pivotal trials of the Watchman device. Discharge after implantation on warfarin or DOAC without concomitant aspirin was associated with lower risk of adverse outcomes." @default.
• W4225284539 created "2022-05-05" @default.
• W4225284539 creator A5001915680 @default.
• W4225284539 creator A5018584633 @default.
• W4225284539 creator A5028022426 @default.
• W4225284539 creator A5029193904 @default.
• W4225284539 creator A5029475706 @default.
• W4225284539 creator A5030903996 @default.
• W4225284539 creator A5040445938 @default.
• W4225284539 creator A5047043395 @default.
• W4225284539 creator A5053800614 @default.
• W4225284539 creator A5062893992 @default.
• W4225284539 creator A5069820090 @default.
• W4225284539 creator A5080340917 @default.
• W4225284539 creator A5081991233 @default.
• W4225284539 creator A5082316876 @default.
• W4225284539 creator A5083358653 @default.
• W4225284539 creator A5083434138 @default.
• W4225284539 date "2022-05-01" @default.
• W4225284539 modified "2023-10-14" @default.
• W4225284539 title "Antithrombotic Therapy After Left Atrial Appendage Occlusion in Patients With Atrial Fibrillation" @default.
• W4225284539 cites W2053482681 @default.
• W4225284539 cites W2054494175 @default.
• W4225284539 cites W2063589187 @default.
• W4225284539 cites W2096246254 @default.
• W4225284539 cites W2096391232 @default.
• W4225284539 cites W2097854437 @default.
• W4225284539 cites W2107050765 @default.
• W4225284539 cites W2112970567 @default.
• W4225284539 cites W2114490057 @default.
• W4225284539 cites W2136489990 @default.
• W4225284539 cites W2152584205 @default.
• W4225284539 cites W2161883207 @default.
• W4225284539 cites W2162508946 @default.
• W4225284539 cites W2278350753 @default.
• W4225284539 cites W24709897 @default.
• W4225284539 cites W2533525745 @default.
• W4225284539 cites W2546858755 @default.
• W4225284539 cites W2564223659 @default.
• W4225284539 cites W2766540689 @default.
• W4225284539 cites W2802541056 @default.
• W4225284539 cites W2912139642 @default.
• W4225284539 cites W2930842499 @default.
• W4225284539 cites W2933459636 @default.
• W4225284539 cites W3013229569 @default.
• W4225284539 cites W3013514162 @default.
• W4225284539 cites W3035828091 @default.
• W4225284539 cites W3150320039 @default.
• W4225284539 cites W4226149068 @default.
• W4225284539 cites W50472604 @default.
• W4225284539 cites W75302244 @default.
• W4225284539 cites W95933110 @default.
• W4225284539 doi "https://doi.org/10.1016/j.jacc.2022.02.047" @default.
• W4225284539 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35512858" @default.
• W4225284539 hasPublicationYear "2022" @default.
• W4225284539 type Work @default.
• W4225284539 citedByCount "27" @default.
• W4225284539 countsByYear W42252845392022 @default.
• W4225284539 countsByYear W42252845392023 @default.
• W4225284539 crossrefType "journal-article" @default.
• W4225284539 hasAuthorship W4225284539A5001915680 @default.
• W4225284539 hasAuthorship W4225284539A5018584633 @default.
• W4225284539 hasAuthorship W4225284539A5028022426 @default.
• W4225284539 hasAuthorship W4225284539A5029193904 @default.
• W4225284539 hasAuthorship W4225284539A5029475706 @default.
• W4225284539 hasAuthorship W4225284539A5030903996 @default.
• W4225284539 hasAuthorship W4225284539A5040445938 @default.
• W4225284539 hasAuthorship W4225284539A5047043395 @default.
• W4225284539 hasAuthorship W4225284539A5053800614 @default.
• W4225284539 hasAuthorship W4225284539A5062893992 @default.
• W4225284539 hasAuthorship W4225284539A5069820090 @default.
• W4225284539 hasAuthorship W4225284539A5080340917 @default.
• W4225284539 hasAuthorship W4225284539A5081991233 @default.
• W4225284539 hasAuthorship W4225284539A5082316876 @default.
• W4225284539 hasAuthorship W4225284539A5083358653 @default.
• W4225284539 hasAuthorship W4225284539A5083434138 @default.
• W4225284539 hasBestOaLocation W42252845391 @default.
• W4225284539 hasConcept C126322002 @default.
• W4225284539 hasConcept C141071460 @default.
• W4225284539 hasConcept C164705383 @default.
• W4225284539 hasConcept C197934379 @default.
• W4225284539 hasConcept C2776301958 @default.
• W4225284539 hasConcept C2777015399 @default.
• W4225284539 hasConcept C2777628954 @default.
• W4225284539 hasConcept C2779161974 @default.
• W4225284539 hasConcept C2780434050 @default.
• W4225284539 hasConcept C71924100 @default.
• W4225284539 hasConceptScore W4225284539C126322002 @default.
• W4225284539 hasConceptScore W4225284539C141071460 @default.
• W4225284539 hasConceptScore W4225284539C164705383 @default.
• W4225284539 hasConceptScore W4225284539C197934379 @default.
• W4225284539 hasConceptScore W4225284539C2776301958 @default.
• W4225284539 hasConceptScore W4225284539C2777015399 @default.
• W4225284539 hasConceptScore W4225284539C2777628954 @default.
• W4225284539 hasConceptScore W4225284539C2779161974 @default.
• W4225284539 hasConceptScore W4225284539C2780434050 @default.
• W4225284539 hasConceptScore W4225284539C71924100 @default.
• W4225284539 hasIssue "18" @default.

• next